MALARIA ERADICATION
THROUGH VACCINATION

Sanaria is a biotechnology company developing vaccines protective against malaria. Sanaria’s vaccines have proven highly protective against Plasmodium falciparum infection in humans.
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Vaccine R&Di-PfSPZ Consortium

Sanaria Celebrates Diwali

Diwali, Deepavali or Dipavali is an Indian festival of lights, which is celebrated every autumn. One of the most popular festivals in India, Diwali symbolises the “victory of light over darkness, good over evil and knowledge over ignorance.” Light is a metaphor for knowledge and consciousness. During the celebration the houses, the streets are decorated with lights. People invite friends and families and celebrate together with good foods, by exchanging gifts and burning the fire crackers. Sanaria and Protein Potential celebrated today with song, dance, and delicious food!

Sanaria and its Bioko Island Malaria Elimination Project partners win the Concordia P3 Impact Award and Audience Choice Award

The Bioko Island Malaria Elimination Project (BIMEP) is a long-term partnership dedicated since 2004 to the elimination of malaria from Equatorial Guinea which had one of the highest rates of malaria transmission and where the disease was the leading cause of morbidity and mortality.

An Urgent Need for Malaria Vaccines


The World Health Organization reports that malaria caused by Plasmodium falciparum results in nearly half a million deaths worldwide annually. Malaria also causes over 200 million clinical cases globally each year. This disease is responsible for a loss of greater than 1% of Africa's GDP, and is a serious concern for travelers and military personnel.

Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.

Global Collaboration: The I-PfSPZ Consortium


Global collaboration, publication and presentation of our work is paramount.

Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.

Subscribe


Join the Sanaria mailing list for updates on our pipeline, events and more.

Our Malaria Vaccine Pipeline


Different scientific approaches. Different strategies for inducing protective immunity.
Innovative routes to success. A major impact in global health.

DONORS & STRATEGIC PARTNERS

Understand the compelling business case for innovative, effective malaria vaccines.

Contact Us


We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Social: